In the News

BEDFORD, Mass., August 21, 2018 – Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries that drive functions of the microbiome organ, today announced that Alison Lawton, Kaleido’s president and chief operating officer (COO), has been appointed to succeed Michael Bonney as chief executive officer. Joshua Brumm has been promoted to COO and will continue to serve as Kaleido’s chief financial officer.  In addition, Mr. Bonney will maintain a leadership role at Kaleido as executive

Read More

BEDFORD, Mass., June 25, 2018 – Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries to drive functions of the microbiome organ, today announced that it has closed $101 million in an oversubscribed Series C financing. Several new investors participated in the financing, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Fidelity Management and Research Company, Invus, and Rock Springs Capital, along with Kaleido’s founder, Flagship Pioneering, and a number of undisclosed

Read More

BEDFORD, Mass., April 23, 2018 – Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Joshua Brumm as chief financial officer. Mr. Brumm, an accomplished CFO with extensive financial and operational experience, will report directly to chief executive officer and chair, Michael Bonney. “We are excited to welcome Josh to our executive team at Kaleido,” said Mr. Bonney. “He has a proven track record of

Read More

BEDFORD, Mass., March 26, 2018 – Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Stephen Sofen, Ph.D., as senior vice president of technical operations, and Susan Stewart, J.D., as senior vice president of regulatory affairs and quality. “We are thrilled to have Steve and Sue join Kaleido,” said Alison Lawton, president and chief operating officer of Kaleido. “Their leadership and significant experience will be

Read More

BEDFORD, Mass. –(BUSINESS WIRE)– Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Wendy Arnold as senior vice president of human resources. Ms. Arnold, who brings more than 20 years of experience in human resources to Kaleido, will report directly to chief executive officer and chair, Michael Bonney. “We are excited to have someone with Wendy’s experience in building HR functions and

Read More

BEDFORD, Mass . –(BUSINESS WIRE)– Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Alison Lawton as president and chief operating officer. Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry. “Alison is a tremendous addition to the Kaleido team,” said Michael Bonney, chief executive officer and chair of Kaleido.

Read More

BEDFORD, Mass. –(BUSINESS WIRE)– Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, announced today the appointment of John W. Davies, Ph.D. as chief technology officer and Michael D. Bruce, Ph.D. as senior vice president, project, portfolio and alliance management. “We are excited to welcome John and Michael to our leadership team,” said Michael Bonney, chief executive officer and chair of Kaleido Biosciences. “We are confident that

Read More

BEDFORD, Mass. –(BUSINESS WIRE)– Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced an agreement with CoreBiome, a genomics platform company focused on accelerating microbiome innovation with expert genomics and big-data analytics, to provide high-scale and high-content microbiome data to increase the speed and productivity of Kaleido’s clinical development and discovery programs. Under the terms of this agreement, Kaleido has committed that over the next 12

Read More

BEDFORD, Mass., Sept. 18, 2017 /PRNewswire/ — Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, announced today the appointment of biopharmaceutical veteran Mike Bonney as chief executive officer and board chair of Kaleido. The Company also announced the completion of an additional capital raise, for a total of $65 million in funds raised to date. The funding will be used to further advance discovery and testing of Kaleido’s novel chemistries for use in

Read More